Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02BAE
|
||||
Former ID |
DIB008587
|
||||
Drug Name |
Synthetic conjugated estrogen
|
||||
Synonyms |
Bijuva; Bithena; DR-2041; SCE-A Vaginal Cream; Synthetic conjugated estrogen (cream, vulvovaginal atrophy); Synthetic conjugated estrogens-A, Barr; Synthetic conjugated estrogens-A, Duramed; Synthetic conjugated estrogen (cream, vulvovaginal atrophy), Teva
|
||||
Indication | Vagina disease [ICD10:N76.0] | Phase 3 | [521865] | ||
Company |
Duramed Pharmaceuticals Inc
|
||||
Target and Pathway | |||||
Target(s) | Estrogen receptor | Target Info | Modulator | [526949], [551871] | |
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
Signaling events mediated by HDAC Class II | |||||
Plasma membrane estrogen receptor signaling | |||||
LKB1 signaling events | |||||
Regulation of Telomerase | |||||
ATF-2 transcription factor network | |||||
AP-1 transcription factor network | |||||
FOXM1 transcription factor network | |||||
Validated nuclear estrogen receptor alpha network | |||||
Signaling mediated by p38-alpha and p38-beta | |||||
FOXA1 transcription factor network | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.